Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Check dcar it will double within a week
* * * Stock Analyzer AKER 4/24/2020
Not one I would have played but still interesting.
Questions?
$AKER "We are providing the immune system with three shots on goal, instead of one, by including S, E, and M together," Prabuddha Kundu, co-founder and managing director at Premas Biotech, said in a statement. https://www.benzinga.com/general/biotech/20/04/15749965/akers-biosciences-rallies-as-ceo-says-company-one-step-closer-to-effective-coronavirus-vaccine-ca
3.7 OS after last weeks offering, at $5 a share only $18m market cap. COD# created a kit and ran from this market cap level to $300 million. AKER may have a strong vaccine candidate and worth $18m, go figure.
Just a $50 million market cap here is $13.50 a share. Like the upside as the company releases more updates and have all their offerings behind them.
Akers Biosciences: Here's Why The Licensing Deal With Premas Biotech Could Be A Game-Changer In The Race For A COVID-19 Vaccine
On March 25th, Akers Biosciences (NasdaqCM: AKER) announced a licensing agreement with Premas Biotech to find an effective vaccine for COVID-19. Premas Biotech has over 125 employees and has delivered over 650 proteins and has completed over 240 separate projects for pharmaceutical companies. The company also has four candidates currently in clinical trials globally, and most notable, an oral insulin drug candidate which recently completed a Phase 2b trial in the U.S.
The transcript from that announcement call explains exactly why Akers and Premas believe that the Akers Biosciences/Premas Biotech partnership has the potential to quickly and cost-effectively bring a yeast-based protein COVID-19 vaccine to market.
https://www.khits.com/story/41978191/akers-biosciences-heres-why-the-licensing-deal-with-premas-biotech-could-be-a-game-changer-in-the-race-for-a-covid-19-vaccine
Akers Biosciences and Premas Biotech Announce Successful Expression of Coronavirus Antigens
Akers Biosciences and Premas Biotech Announce Successful Expression of Coronavirus Antigens
Thorofare, New Jersey, April 08, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the "Company") (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed a second milestone, the successful expression of the three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M), that were selected for their vaccine candidate. The antigens have been expressed using the D-Crypt(TM) platform at Premas Biotech, which utilizes its vectors and S cerevisiae strain. Premas is now moving forward with purification and post-expression processing, which we believe should lead to a scaling up of the antigens.
Prabuddha Kundu, Co-Founder and Managing Director at Premas Biotech, commented, "We are happy to announce our success in expressing all three antigens. We continue to believe that the immune system is better served with three shots on goal and our inclusion of the S, E, and M antigens together should enhance the efficacy of our vaccine candidate. We are also pleased with the expedited nature of our milestones thus far, which is a positive step towards our goal to reach clinical trials."
Christopher Schreiber, Executive Chairman of Akers, stated, "We are now halfway through our four-milestone plan that we believe will allow us to commence clinical trials. Our partnership with Premas is executing very well and we look forward to sharing the next milestones as they occur in the weeks to come."
About Premas Biotech
Premas Biotech develops novel technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates. Premas' key focus areas are infectious diseases, cancer, metabolic disorders and inflammation. Besides D-Crypt(TM) the difficult to express proteins expression platform, Premas' leading technologies include Axtex-4D(TM) : an ex-vivo tissueoid generation platform and C-Qwence(TM) : a fully human naive India based scFv antibody library. Further information is available on the Company's website: www.premasbiotech.com
Great Article!- AKER got top mention as a vaccine. That is really hot that analysts are picking up on this. https://insiderfinancial.com/uk-prime-minister-boris-johnson-linkage-to-cytodyn-otcmkts-cydy-evolving/179800/
A vaccine is in high demand, (see the bold), if they get approval shortly like Moderna, see you over $25 in a blink. Could come any day..
+$$$ AKER
Results posted; targeted for additional trades.
By the time it is finalized, and other news or developments are released the anticipated price might be well higher than current price.
Sometimes thee releases are clues to buy in advance of that
* * $AKER Video Chart 04-07-2020 * *
Link to Video - click here to watch the technical chart video
i'm in at 3.80 a share so let it rip
Why pay six dollars when you could buy on open market for a cheaper?
Agree, 766,667 shares of the Company's common stock, at a purchase price of $6.00 per share. That's less than 2% of just today's volume. Insanely low float is going to fly in due time. Hope the shorts are piling in to help it out..
Yes should see a bounce here at the end of the day .. public offering was minuscule
$5.55 now. Post marked. Just means a huge run in store when the "sell" calls come. Always bank huge.
LMFAO. There was one a few hours ago. Haahaa! Clumsy ass..
Crash coming very soon. Probably offering AH
Looking forward to after hours here. Would also love them to drop a PR in the AM. Straight to $8+
Not for awhile..
Agree, it's here..
$AKER back to $3.00 Dilution
should bouncing to $10
imo
sounds very very good
Barely 700K shares in the offering and it was done at $6. This SS is still insanely low. Hopefully shorts are piling in here, and then they rocket it. They can put out news after hours or premarket and this could be $15+ in a blink, have to be in to win. I think $6 is a good entry point.
Hope so for your sake. Got in yesterday on a hope for a POP today. Consider myself lucky to get out in the 8.30 range as I of course had no idea what it would do at open today. JMHO but even if it closes green today it most likely will close red tomorrow. Again , just an opinion from other past experiences. GLTU
Already several million of shares exchanged since the offering announcement!
So, shall we presume that the circa 700k shares to be sold at the market have already been sold? If not then when, any idea?
It wasn't if, but more like when they were going to pull what so many other biotech company's also do so often, when they are stocks that just trading at a few bucks days ago, and have a huge multi dollars run up, is end up screwing over the late to the game buyers, by saying bend over investors were going to spread you wide open
Was waiting for this to happen to get in. Only 766K shares and at $6? That's not bad at all! I'm in at $6. This will move nicely from here once it settles down!
Akers Biosciences Announces $4.6 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
April 07, 2020 10:53 ET | Source: Akers Biosciences Inc.
Thorofare, New Jersey, April 07, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 766,667 shares of the Company’s common stock, at a purchase price of $6.00 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about April 9, 2020, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The gross proceeds to the Company from this offering are expected to be approximately $4.6 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use $250,000 of the net proceeds from this offering to pay the former members of Cystron Biotech, LLC, pursuant to the terms of that certain Membership Interest Purchase Agreement, dated as of March 23, 2020, and the remaining net proceeds from this offering for working capital and general corporate purposes.
The shares of common stock are being offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-234449) previously filed with the Securities and Exchange Commission (the "SEC") on November 1, 2019, and declared effective by the SEC on April 7, 2020. The offering of the securities is made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the securities being offered will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC's website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (646) 975-6996 or e-mail at placements@hcwco.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
I told you this will move fast.
Never saw that before, twice in 30mins.
Halting is a price killer....
i don't understand. what happened?
I don’t really understand this mornings news about aker. Can someone simplify it for me. Thanks
The open PPS should be more solid/interesting for today's activity but looking GOOD for now
$AKER Akers Biosciences Rallies As CEO Says Company 'One Step Closer' To Effective Coronavirus Vaccine Candidate https://www.benzinga.com/general/biotech/20/04/15749965/akers-biosciences-rallies-as-ceo-says-company-one-step-closer-to-effective-coronavirus-vaccine-ca?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+benzinga+%28Benzinga+News+Feed%29
Buy low / sell high
$AKER The 1 analysts offering 12-month price forecasts for Akers Biosciences Inc have a median target of 768.00, with a high estimate of 768.00 and a low estimate of 768.00. The median estimate represents a +18,273.21% increase from the last price of 4.18. https://money.cnn.com/quote/forecast/forecast.html?symb=aker
$AKER $7 open imo
Followers
|
90
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2221
|
Created
|
01/15/15
|
Type
|
Free
|
Moderators |
Akers Biosciences mission is dedicated to solving global health challenges. Akers was founded in 1989 and has over
30 years of success in the health diagnostic industry having developed proprietary, in vitro diagnostic technologies.
In March of 2020, in an attempt to further their mission, Akers announced a strategic partnership with Premas Biotech.
The partnerships primary objective is to focus on novel vaccine candidates.
The emergence of this pandemic offers an opportunity for the company to be a solution in the healthcare space,
one that sets the stage for our next chapter of growth.
Akers Biosciences Schedules Conference Call to Discuss Licensing Announcement with Premas Biotech for a Coronvirus Vaccine Candidate
Premas develops novel & transformational technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates.
Akers licensed a novel coronavirus vaccine candidate under development by Premas using Premas’ genetically engineered S. cerevisiae platform, D-Crypt™.
The Premas platform has three key advantages which will set this vaccine candidate apart from industry peers.
Premas successfully cloned three Coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) in the first quarter of 2020 which further differentiates our vaccine candidate.
We aim to provide the immune system with several opportunities to identify the virus; a design concept extremely important for efficacy and our future success.
We held a conference call with Prabuddha Kundu, Co-Founder and Managing Director at Premas Biotech, in late March.
The transcript, which provides additional information on our philosophy and milestone timeline, can be accessed here.
PIFA® technology is a cutting-edge, patented immunoassay method which rapidly, easily, and accurately detects target antigens or antibodies.
PIFA® technology is based on the selective filtration of microparticles in response to antibody/antigen binding.
Dyed microparticles coated with antigens or antibodies determine the visual signal for the results of the assay.
The presence of a corresponding antibody or antigen in the test sample results in the formation of a matrix of microparticles, which are more susceptible to filtration.
The inability of these matrixed microparticles to move through the filter, and the resulting color change in the reagent mixture,
signal positive reactivity of the test sample (e.g. the presence of target antigens or antibodies).
Key features of PIFA® technology make it advantageous for a broad array of uses:
PIFA® technology is currently used in:
Licensing Availability
PIFA® technology is available for licensing. To inquire about licensing or for technical inquiries, please contact us.
Patent Information
Shs Outstand | 8.72M
|
Insider Trans | -0.83%
|
Book/sh | 2.96 |
Cash/sh | 2.00 |
Debt/Eq NO DEBT | 0.00 |
52W Range | 1.55 - 12.72 |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |